Premium
X‐waiver battle over buprenorphine heats up
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30558
Subject(s) - waiver , buprenorphine , (+) naloxone , medicine , food and drug administration , license , opioid use disorder , schedule , opioid , pharmacology , law , computer science , political science , receptor , operating system
As buprenorphine — a schedule III medication approved for the treatment of opioid use disorder when provided in a combination product (that includes naloxone), such as Suboxone — has special prescribing requirements. No matter how thorough your training as a clinician, you have to receive an X‐waiver from the Drug Enforcement Administration (DEA), in addition to your DEA license, in order to be able to prescribe it.